How Much Upside is Left in Nextracker (NXT)? Wall Street Analysts Think 25.28% — Positive
NXT Zacks Investment Research — February 10, 2025The consensus price target hints at a 25.3% upside potential for Nextracker (NXT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Archer Aviation (ACHR) Could Surge 25.61%: Read This Before Placing a Bet — Positive
ACHR Zacks Investment Research — February 10, 2025The mean of analysts' price targets for Archer Aviation (ACHR) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Best Momentum Stocks to Buy for February 10th — Positive
BSX CFR ENVA Zacks Investment Research — February 10, 2025BSX, ENVA and CFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 10, 2025.

An improving economy, steepening of the yield curve, and improved investment banking and trading operations have been helping bank ETFs lately.

Huntsman (HUN) Expected to Beat Earnings Estimates: Should You Buy? — Positive
HUN Zacks Investment Research — February 10, 2025Huntsman (HUN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Noble Corporation PLC (NE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release — Positive
NE Zacks Investment Research — February 10, 2025Noble Corporation PLC (NE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wells Fargo Upgraded These 3 Stocks—Here's Why They Stand Out — Positive
CLX MPC SPOT MarketBeat — February 10, 2025Now that the first quarter of 2025 is underway, investors across the board are probably looking to find the best ideas to get their portfolios started on the right foot. This way, they can have not only the momentum but also the liquidity necessary to chase the growth plays that will become available in later months.

It's been a bumpy start to 2025 for bitcoin and the broader cryptocurrency universe. Amid soaring optimism that this year could be a tipping point for bitcoin and other digital currencies, trade tariffs and indications inflation remains are among the factors weighing on risk assets.

Addus HomeCare Announces Fourth Quarter and Year-end 2024 Earnings Release and Conference Call — Neutral
ADUS Business Wire — February 10, 2025FRISCO, Texas--(BUSINESS WIRE)--Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, announced today that it will release earnings for the fourth quarter and year-ended December 31, 2024, on Monday, February 24, 2025, after the market close. Addus HomeCare will host a conference call on Tuesday, February 25, 2025, at 9:00 a.m. Eastern Time. Joining the call from the Company will be Dirk Allison, Chairman and CEO, Brian Poff, Executive Vice President and CFO, and Brad Bic.

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Pacira BioSciences, Inc. — Neutral
PCRX Accesswire — February 10, 2025LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 2, 2023 to August 8, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 14, 2025.

The Schall Law Firm Invites Investors With Losses In Fluence Energy, Inc. To Join A Securities Fraud Investigation — Neutral
FLNC Accesswire — February 10, 2025LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fluence Energy, Inc. ("Fluence" or "the Company") (NASDAQ:FLNC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Shareholders With Losses In Silvaco Group, Inc. To Join A Securities Fraud Investigation — Neutral
SVCO Accesswire — February 10, 2025LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Silvaco Group, Inc. ("Silvaco" or "the Company") (NASDAQ:SVCO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Transocean Ltd. — Neutral
RIG Accesswire — February 10, 2025LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Transocean Ltd. ("Transocean" or "the Company") (NYSE:RIG) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Nextracker Inc. — Neutral
NXT Accesswire — February 10, 2025LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nextracker Inc. ("Nextracker" or "the Company") (NASDAQ:NXT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 1, 2024 and August 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before February 25, 2025.

The Schall Law Firm Invites Investors With Losses In Liberty TripAdvisor Holdings, Inc. To Join A Securities Fraud Investigation — Neutral
LTRPA Accesswire — February 10, 2025LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Liberty TripAdvisor Holdings, Inc. ("Liberty TripAdvisor" or "the Company") (OTCQB:LTRPA) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Liberty TripAdvisor board breached its fiduciary duties to shareholders.

Vacasa, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm — Neutral
VCSA Accesswire — February 10, 2025LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Vacasa, Inc. ("Vacasa" or "the Company") (NASDAQ:VCSA) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Vacasa board breached its fiduciary duties to shareholders.

AstraZeneca PLC Is Being Sued For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm — Neutral
AZN Accesswire — February 10, 2025LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before February 21, 2025.

The Schall Law Firm Invites Investors With Losses In Celanese Corporation To Join A Securities Fraud Investigation — Neutral
CE Accesswire — February 10, 2025LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Celanese Corporation ("Celanese" or "the Company") (NYSE:CE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc. — Neutral
REGN Accesswire — February 10, 2025LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 2, 2023 and October 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 10, 2025.

The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Applied Therapeutics, Inc. — Neutral
APLT Accesswire — February 10, 2025LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 3, 2024 and December 2, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before February 18, 2025.
